The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

NCT02327039 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

University of Padova

Collaborators

[object Object]